Hence, we can conclude from these data that the circulating levels of the oncosuppressor miR-579-3p and of the oncomiR miR-4488 are able to identify BRAF-mutated melanoma patients who benefit or not from target therapy with BRAF and MEK inhibitors. Here, MAP2K7 is linked to melanoma.